Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(67%)

Phase Distribution

Ph not_applicable
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

terminated267%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
terminatednot_applicable

Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS

NCT02252094
completednot_applicable

Neurally Adjusted Ventilatory Assist (NAVA) Study in Adults With Acute Respiratory Failure

NCT01730794
terminatednot_applicable

Does Automated Closed-Loop Ventilation Reduce the DRiving Pressure Levels in Patients With ARDS

NCT03211494

Clinical Trials (3)

Showing 3 of 3 trials
NCT02252094Not Applicable

Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS

Terminated
NCT01730794Not Applicable

Neurally Adjusted Ventilatory Assist (NAVA) Study in Adults With Acute Respiratory Failure

Completed
NCT03211494Not Applicable

Does Automated Closed-Loop Ventilation Reduce the DRiving Pressure Levels in Patients With ARDS

Terminated

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3